119 related articles for article (PubMed ID: 38689576)
1. Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities?
Freeman JQ; Huo D
Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):635-637. PubMed ID: 38689576
[TBL] [Abstract][Full Text] [Related]
2. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
3. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
4. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
[No Abstract] [Full Text] [Related]
5. Underutilization of gene expression profiling for early-stage breast cancer in California.
Cress RD; Chen YS; Morris CR; Chew H; Kizer KW
Cancer Causes Control; 2016 Jun; 27(6):721-7. PubMed ID: 27097910
[TBL] [Abstract][Full Text] [Related]
6. Low utility of Oncotype DX® in the clinic.
Ricks-Santi LJ; McDonald JT
Cancer Med; 2017 Mar; 6(3):501-507. PubMed ID: 28145091
[TBL] [Abstract][Full Text] [Related]
7. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
[TBL] [Abstract][Full Text] [Related]
8. Adherence Disparities and Utilization Trends of Oncotype Dx Assay: A National Cancer Database Study.
Chen S; Thacker C; Wang S; Young KA; Hoffman RL; Blansfield JA
J Surg Res; 2023 Jun; 286():65-73. PubMed ID: 36758322
[TBL] [Abstract][Full Text] [Related]
9. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
10. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
[TBL] [Abstract][Full Text] [Related]
11. Understanding Racial and Ethnic Inequities in Uptake and Outcomes Following Multigene Prognostic Testing in Early Breast Cancer: The Promise of Real-World Data.
Wang X; Cho-Phan CD; Hoskins KF; Calip GS
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):704-706. PubMed ID: 35373264
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
13. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
14. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
[TBL] [Abstract][Full Text] [Related]
15. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
16. Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment.
Kozick Z; Hashmi A; Dove J; Hunsinger M; Arora T; Wild J; Shabahang M; Blansfield J
Am J Surg; 2018 Apr; 215(4):686-692. PubMed ID: 28606707
[TBL] [Abstract][Full Text] [Related]
17. Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.
Acuna N; Plascak JJ; Tsui J; Stroup AM; Llanos AAM
Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34065945
[TBL] [Abstract][Full Text] [Related]
18. Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer.
Roberts MC; Kurian AW; Petkov VI
J Natl Compr Canc Netw; 2019 Jun; 17(6):662-668. PubMed ID: 31200352
[TBL] [Abstract][Full Text] [Related]
19. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care.
Freedman RA; Virgo KS; He Y; Pavluck AL; Winer EP; Ward EM; Keating NL
Cancer; 2011 Jan; 117(1):180-9. PubMed ID: 20939011
[TBL] [Abstract][Full Text] [Related]
20. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Carlson JJ; Roth JA
Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
